Zymeworks reports phase 1 data for cancer drug ZW191

June 14, 2026 6:05 PM

Zymeworks Inc. (NASDAQ: ZYME) presented clinical data for its experimental cancer treatment ZW191 at the European Society for Medical Oncology ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found